dtrm-555
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2016 (NCT02900716)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- dtrm-555
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04305444 | Phase 2 | Mar 31, 2020 | Memorial Sloan-Kettering Cancer Center, Zhejiang DTRM Biopharma |
| NCT02900716 | Phase 1 | Sep 1, 2016 | Zhejiang DTRM Biopharma |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Zhejiang DTRM Biopharma | For profit | 2 | 2 | 2 | 2016 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1